Pharma Mar Utdelningar och återköp
Utdelning kriterier kontrolleras 2/6
Pharma Mar är ett utdelningsbetalande företag med en aktuell avkastning på 1.31% som täcks väl av vinsten.
Viktig information
1.3%
Avkastning på utdelning
0.6%
Återköpsavkastning
| Total avkastning till aktieägarna | 1.9% |
| Framtida utdelningsavkastning | 1.5% |
| Utdelningstillväxt | 9.5% |
| Nästa utbetalningsdag för utdelning | n/a |
| Ex utdelningsdag | n/a |
| Utdelning per aktie | n/a |
| Utdelningsandel | 32% |
Senaste utdelnings- och återköpsuppdateringar
Analysartikel • Jun 16
Pharma Mar (BME:PHM) Will Pay A Larger Dividend Than Last Year At €0.80
Pharma Mar, S.A.'s ( BME:PHM ) dividend will be increasing from last year's payment of the same period to €0.80 on 27th...Analysartikel • May 23
Pharma Mar (BME:PHM) Has Announced That It Will Be Increasing Its Dividend To €0.80
Pharma Mar, S.A. ( BME:PHM ) will increase its dividend from last year's comparable payment on the 27th of June to...Analysartikel • Jun 01
Pharma Mar (BME:PHM) Will Pay A Larger Dividend Than Last Year At €0.65
Pharma Mar, S.A.'s ( BME:PHM ) dividend will be increasing from last year's payment of the same period to €0.65 on 14th...Recent updates
Analysartikel • Aug 01
Analyst Estimates: Here's What Brokers Think Of Pharma Mar, S.A. (BME:PHM) After Its Half-Yearly Report
Last week saw the newest half-yearly earnings release from Pharma Mar, S.A. ( BME:PHM ), an important milestone in the...
Uppdatering av berättelse • Jul 10
PHM: Future Cancer Trial Progress And New Lung Cancer Approvals Will Matter
Analysts have raised their 12-month price target for Pharma Mar from €75 to €90, citing updated assumptions around fair value, discount rate, revenue growth, profit margin and expected future P/E following new Street research coverage. What’s in the News for Pharma Mar Pharma Mar started a Phase 1/2 clinical trial of PM54 in combination with pembrolizumab for previously treated patients with advanced solid tumors, following US FDA IND approval in December 2025.
Uppdatering av berättelse • Jun 25
PHM: First Line Lung Cancer Maintenance Approvals Will Support Medium Term Upside
Analysts have reset their 12 month price target for Pharma Mar to €125, reflecting updated assumptions around a slightly higher discount rate, modestly stronger projected revenue growth and profit margins, and a marginally lower future P/E, while citing supportive recent Street research coverage. What’s in the News for Pharma Mar Zepzelca (lurbinectedin) did not meet the primary overall survival endpoint in the Phase III LAGOON confirmatory trial for relapsed metastatic small cell lung cancer, according to Jazz Pharmaceuticals and Pharma Mar.Uppdatering av berättelse • Jun 06
PHM: Asia Pacific Lung Cancer Approvals Will Drive Medium Term Upside Potential
Analysts have maintained their €125 price target on Pharma Mar, citing BTIG's recent bullish initiation and updated assumptions for slightly higher revenue, profit margins, and a modestly lower discount rate and P/E multiple. What's in the News European Commission approves Zepzelca (lurbinectedin) with atezolizumab (Tecentriq) as first-line maintenance therapy for adult patients with extensive-stage small cell lung cancer whose disease has not progressed after standard induction therapy, following a positive opinion from the EMA, based on the phase 3 IMforte trial (source: company announcement).Uppdatering av berättelse • May 21
PHM: Asia Pacific Lung Cancer Expansion Will Support Medium Term Upside Potential
Analysts have raised their price target on Pharma Mar from €118 to €125, citing new research that reflects updated assumptions on growth, profitability and future P/E expectations following fresh coverage with a bullish stance. Analyst Commentary Recent Street research coverage reflects a confident tone around Pharma Mar, with bullish analysts pointing to updated assumptions on growth, profitability and future P/E expectations as key supports for higher valuation ranges.Analysartikel • May 09
Pharma Mar's (BME:PHM) Solid Profits Have Weak Fundamentals
Despite posting some strong earnings, the market for Pharma Mar, S.A.'s ( BME:PHM ) stock hasn't moved much. We did...Analysartikel • Nov 07
There May Be Underlying Issues With The Quality Of Pharma Mar's (BME:PHM) Earnings
Pharma Mar, S.A.'s ( BME:PHM ) robust earnings report didn't manage to move the market for its stock. We did some...Analysartikel • Nov 02
Pharma Mar, S.A. (BME:PHM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Pharma Mar, S.A. ( BME:PHM ) last week reported its latest third-quarter results, which makes it a good time for...Analysartikel • Oct 29
Is Pharma Mar (BME:PHM) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysartikel • Aug 03
Risks To Shareholder Returns Are Elevated At These Prices For Pharma Mar, S.A. (BME:PHM)
It's not a stretch to say that Pharma Mar, S.A.'s ( BME:PHM ) price-to-sales (or "P/S") ratio of 7.4x right now seems...Analysartikel • Jun 16
Pharma Mar (BME:PHM) Will Pay A Larger Dividend Than Last Year At €0.80
Pharma Mar, S.A.'s ( BME:PHM ) dividend will be increasing from last year's payment of the same period to €0.80 on 27th...Analysartikel • May 23
Pharma Mar (BME:PHM) Has Announced That It Will Be Increasing Its Dividend To €0.80
Pharma Mar, S.A. ( BME:PHM ) will increase its dividend from last year's comparable payment on the 27th of June to...
Ny berättelse • Mar 09
ZEPZELCA's EMA Submission Will Broaden Cancer Treatment Availability In Europe
Successful approval of ZEPZELCA in Europe and new markets could significantly boost PharmaMar’s future revenues, leveraging positive trial results.Analysartikel • Mar 06
We Think Shareholders Should Be Aware Of Some Factors Beyond Pharma Mar's (BME:PHM) Profit
The latest earnings release from Pharma Mar, S.A. ( BME:PHM ) disappointed investors. Our analysis found several...Analysartikel • Feb 13
There's Reason For Concern Over Pharma Mar, S.A.'s (BME:PHM) Massive 27% Price Jump
The Pharma Mar, S.A. ( BME:PHM ) share price has done very well over the last month, posting an excellent gain of 27...Analysartikel • Oct 16
Pharma Mar, S.A.'s (BME:PHM) Price Is Right But Growth Is Lacking After Shares Rocket 55%
Pharma Mar, S.A. ( BME:PHM ) shares have continued their recent momentum with a 55% gain in the last month alone. The...Analysartikel • Jul 28
Pharma Mar, S.A.'s (BME:PHM) Share Price Boosted 27% But Its Business Prospects Need A Lift Too
Pharma Mar, S.A. ( BME:PHM ) shares have continued their recent momentum with a 27% gain in the last month alone...Analysartikel • Jun 01
Pharma Mar (BME:PHM) Will Pay A Larger Dividend Than Last Year At €0.65
Pharma Mar, S.A.'s ( BME:PHM ) dividend will be increasing from last year's payment of the same period to €0.65 on 14th...Analysartikel • May 28
Pharma Mar, S.A.'s (BME:PHM) Shares Bounce 29% But Its Business Still Trails The Industry
Pharma Mar, S.A. ( BME:PHM ) shareholders would be excited to see that the share price has had a great month, posting a...Analysartikel • Mar 03
Pharma Mar, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Last week, you might have seen that Pharma Mar, S.A. ( BME:PHM ) released its annual result to the market. The early...Analysartikel • Jan 25
Here's Why Pharma Mar (BME:PHM) Has A Meaningful Debt Burden
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysartikel • Apr 28
Pharma Mar, S.A. (BME:PHM) Shares Could Be 30% Below Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, Pharma Mar fair value estimate is €52.37 Pharma Mar is...Stabilitet och tillväxt i betalningar
Hämta utdelningsdata
Stabil utdelning: Även om utdelningen har varit stabil, har PHM betalat ut en utdelning i mindre än 10 år.
Växande utdelning: PHM s utdelning har ökat, men företaget har bara betalat ut en utdelning i 7 år.
Utdelningsavkastning jämfört med marknaden
| Pharma Mar Utdelningsavkastning jämfört med marknaden |
|---|
| Segment | Utdelningsavkastning |
|---|---|
| Företag (PHM) | 1.3% |
| Marknadens lägsta 25% (ES) | 1.9% |
| Marknad Topp 25% (ES) | 5.1% |
| Genomsnitt för branschen (Biotechs) | 2.3% |
| Prognosanalytiker (PHM) (upp till 3 år) | 1.5% |
Anmärkningsvärd utdelning: PHM s utdelning ( 1.31% ) är inte märkbar jämfört med de lägsta 25 % av utdelningsbetalarna på Spanish marknaden ( 1.93% ).
Hög utdelning: PHM s utdelning ( 1.31% ) är låg jämfört med de översta 25 % av utdelningsbetalarna på Spanish marknaden ( 5.06% ).
Vinstutdelning till aktieägarna
Resultattäckning: Med sin rimligt låga utbetalningskvot ( 32.1% ), täcks PHM s utdelningsbetalningar väl av intäkter.
Kontantutbetalning till aktieägarna
Kassaflödestäckning: Med sin ganska låga cash payout_ratio ( 33.9% ), täcks PHM s utdelningsbetalningar väl av kassaflöden.
Upptäck bolag med stark utdelning
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/09/13 03:46 |
| Aktiekurs vid dagens slut | 2026/09/11 00:00 |
| Intäkter | 2026/06/30 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Pharma Mar, S.A. bevakas av 12 analytiker. 8 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Jaime Escribano | Banco Santander |
| Patricia Cifuentes | Bestinver Sociedad De Valores, S.A |
| Kambiz Yazdi | BTIG |